ADVM - アバランシェ・バイオテクノロジ―ズ (Adverum Biotechnologies Inc.) アバランシェ・バイオテクノロジ―ズ

 ADVMのチャート


 ADVMの企業情報

symbol ADVM
会社名 Adverum Biotechnologies Inc (アバランシェ・バイオテクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Adverum Biotechnologies Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research develop and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing specifically in process development and assay development.   アバランシェ・バイオテクノロジ―ズは、米国のバイオ医薬品会社。眼科疾患用の新規遺伝子治療薬の発見、開発および商業化に従事。主な製品は、滲出型加齢黄斑変性症の遺伝子治療薬「AVA-101」やX染色体連鎖性網膜分離症(XLRS)の遺伝子治療薬「AVA-311」。本社は、カリフォルニア州メンロ・パ―ク。   Adverum Biotechnologies, publicly traded is a clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, designed as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. On May 12, 2016, Adverum formed as a company after the closing on a transaction with Annapurna Therapeutics. The company announced its common stock will begin trading on Nasdaq under the symbol ADVM as of the open of market.
本社所在地 1035 O'Brien Drive Menlo Park CA 94025 USA
代表者氏名 Paul B. Cleveland ポールB.クリーブランド
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-272-6269
設立年月日 38899
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 78人
url www.avalanchebiotech.com
nasdaq_url https://www.nasdaq.com/symbol/advm
adr_tso
EBITDA EBITDA(百万ドル) -65.87600
終値(lastsale) 5.51
時価総額(marketcap) 345444347.74
時価総額 時価総額(百万ドル) 359.86400
売上高 売上高(百万ドル) 1.63300
企業価値(EV) 企業価値(EV)(百万ドル) 124.98800
当期純利益 当期純利益(百万ドル) -54.46500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Adverum Biotechnologies Inc revenues decreased 23% to $709K. Net loss increased 31% to $36M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development -gross increase of 39% to $20.8M (expense) Stock-based Compensation in SGA increase from $1.5M to $6.1M (expense).

 ADVMのテクニカル分析


 ADVMのニュース

   LifeSci Capital Stick to Their Buy Rating for Adverum Biotechnologies  2020/11/06 02:45:51 Investing.com
LifeSci Capital Stick to Their Buy Rating for Adverum Biotechnologies
   Adverum Biotechnologies (NASDAQ:ADVM) Stock Price Up 5.2%  2020/10/22 19:56:50 US Banking News
Adverum Biotechnologies Inc (NASDAQ:ADVM)’s stock price rose 5.2% during trading on Thursday . The stock traded as high as $12.47 and last traded at $12.29. Approximately 723,601 shares changed hands during mid-day trading, a decline of 47% from the average daily volume of 1,376,595 shares. The stock had previously closed at $11.68. Several equities analysts […]
   Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock  2020/08/13 01:37:44 GlobeNewswire
REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting…
   Adverum Biotechnologies : Virtual IR/KOL Event August 10, 2020 | MarketScreener  2020/08/10 22:04:05 MarketScreener
Virtual IR/KOL Event August 10, 2020 Forward-looking Statements Statements contained in… | August 11, 2020
   Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results  2020/08/10 20:00:00 GlobeNewswire
-- Continued robust treatment response from both high and low doses -- -- Long-term durability beyond 15 months from single IVT injection with zero…
   LifeSci Capital Stick to Their Buy Rating for Adverum Biotechnologies  2020/11/06 02:45:51 Investing.com
LifeSci Capital Stick to Their Buy Rating for Adverum Biotechnologies
   Adverum Biotechnologies (NASDAQ:ADVM) Stock Price Up 5.2%  2020/10/22 19:56:50 US Banking News
Adverum Biotechnologies Inc (NASDAQ:ADVM)’s stock price rose 5.2% during trading on Thursday . The stock traded as high as $12.47 and last traded at $12.29. Approximately 723,601 shares changed hands during mid-day trading, a decline of 47% from the average daily volume of 1,376,595 shares. The stock had previously closed at $11.68. Several equities analysts […]
   Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock  2020/08/13 01:37:44 GlobeNewswire
REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting…
   Adverum Biotechnologies : Virtual IR/KOL Event August 10, 2020 | MarketScreener  2020/08/10 22:04:05 MarketScreener
Virtual IR/KOL Event August 10, 2020 Forward-looking Statements Statements contained in… | August 11, 2020
   Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results  2020/08/10 20:00:00 GlobeNewswire
-- Continued robust treatment response from both high and low doses -- -- Long-term durability beyond 15 months from single IVT injection with zero…
   Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock  2020/08/13 01:37:44 GlobeNewswire
REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting…
   Adverum Biotechnologies : Virtual IR/KOL Event August 10, 2020 | MarketScreener  2020/08/10 22:04:05 MarketScreener
Virtual IR/KOL Event August 10, 2020 Forward-looking Statements Statements contained in… | August 11, 2020
   Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results  2020/08/10 20:00:00 GlobeNewswire
-- Continued robust treatment response from both high and low doses -- -- Long-term durability beyond 15 months from single IVT injection with zero…
   Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update  2020/07/29 20:05:00 GlobeNewswire
REDWOOD CITY, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting…
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アバランシェ・バイオテクノロジ―ズ ADVM Adverum Biotechnologies Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)